Across TCGA pan-cancer cohorts, MTHFD1 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MTHFD1 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MTHFD1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MTHFD1 expression acts as an unfavorable survival marker.
UCEC are the cancer types where MTHFD1 Mutation most reproducibly stratifies survival.